Literature DB >> 16136555

Effect of galactose density on asialoglycoprotein receptor-mediated uptake of galactosylated liposomes.

Chittima Managit1, Shigeru Kawakami, Fumiyoshi Yamashita, Mitsuru Hashida.   

Abstract

Galactosylated (Gal) liposomes containing various molar ratios of cholesten-5-yloxy-N-(4-((1-imino-2-D-thiogalactosylethyl)formamide (Gal-C4-Chol) as a ligand for asialoglycoprotein receptors were prepared to study the effect of the galactose content of Gal-liposomes labeled with [3H]cholesteryl hexadecyl ether on their targeted delivery to hepatocytes. The uptake characteristics of Gal-liposomes having Gal-C4-Chol of 1.0%, 2.5%, 3.5%, 5.0%, and 7.5% were evaluated. The uptake and internalization by HepG2 cells was enhanced by the addition of Gal-C4-Chol to the Gal-liposomes. In the presence of excess galactose, the uptake of Gal-liposomes having Gal-C4-Chol of 3.5%, 5.0%, and 7.5% was inhibited suggesting asialoglycoprotein receptor mediated uptake. After intravenous injection, Gal-liposomes having Gal-C4-Chol of 3.5%, 5.0%, and 7.5%, rapidly disappeared from the blood and exhibited rapid liver accumulation with up to about 80% of the dose within 10 min whereas Gal-liposomes having low Gal-C4-Chol (1.0% and 2.5%) showed a slight improvement in liver accumulation compared with bare-liposomes. Gal-liposomes with high Gal-C4-Chol are preferentially taken up by hepatocytes and the highest uptake ratio by parenchymal cells (PC) and nonparenchymal cells (NPC) (PC/NPC ratio) was observed with Gal-liposomes having of 5.0% Gal-C4-Chol. We report here that the galactose density of Gal-liposomes prepared by Gal-C4-Chol is important for both effective recognition by asialoglycoprotein receptors and cell internalization. Copyright (c) 2005 Wiley-Liss, Inc. and the American Pharmacists Association

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16136555     DOI: 10.1002/jps.20443

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  15 in total

Review 1.  Therapeutic targeting of liver inflammation and fibrosis by nanomedicine.

Authors:  Matthias Bartneck; Klaudia Theresa Warzecha; Frank Tacke
Journal:  Hepatobiliary Surg Nutr       Date:  2014-12       Impact factor: 7.293

Review 2.  Recent strategies towards the surface modification of liposomes: an innovative approach for different clinical applications.

Authors:  Amjad Ali Khan; Khaled S Allemailem; Saleh A Almatroodi; Ahmed Almatroudi; Arshad Husain Rahmani
Journal:  3 Biotech       Date:  2020-03-10       Impact factor: 2.406

3.  Mannan-modified solid lipid nanoparticles for targeted gene delivery to alveolar macrophages.

Authors:  Wangyang Yu; Chunxi Liu; Yu Liu; Na Zhang; Wenfang Xu
Journal:  Pharm Res       Date:  2010-04-27       Impact factor: 4.200

4.  Sustained liver targeting and improved antiproliferative effect of doxorubicin liposomes modified with galactosylated lipid and PEG-lipid.

Authors:  Shaoning Wang; Hui Xu; Jinghua Xu; Ying Zhang; Yingchun Liu; Yi-hui Deng; Dawei Chen
Journal:  AAPS PharmSciTech       Date:  2010-05-19       Impact factor: 3.246

Review 5.  Nanovehicular intracellular delivery systems.

Authors:  Ales Prokop; Jeffrey M Davidson
Journal:  J Pharm Sci       Date:  2008-09       Impact factor: 3.534

Review 6.  Nano-vectors for efficient liver specific gene transfer.

Authors:  Atul Pathak; Suresh P Vyas; Kailash C Gupta
Journal:  Int J Nanomedicine       Date:  2008

7.  Anti-tumor effect of all-trans retinoic acid loaded polymeric micelles in solid tumor bearing mice.

Authors:  Narin Chansri; Shigeru Kawakami; Masayuki Yokoyama; Tatsuhiro Yamamoto; Pensri Charoensit; Mitsuru Hashida
Journal:  Pharm Res       Date:  2007-07-31       Impact factor: 4.200

8.  Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma.

Authors:  Xiaoju Zhou; Mengzi Zhang; Bryant Yung; Hong Li; Chenguang Zhou; L James Lee; Robert J Lee
Journal:  Int J Nanomedicine       Date:  2012-10-16

9.  Ultrasound exposure improves the targeted therapy effects of galactosylated docetaxel nanoparticles on hepatocellular carcinoma xenografts.

Authors:  Hongfen Wei; Jing Huang; Jing Yang; Xiujuan Zhang; Liwu Lin; Ensheng Xue; Zhikui Chen
Journal:  PLoS One       Date:  2013-03-01       Impact factor: 3.240

10.  Synthesis of novel tetravalent galactosylated DTPA-DSPE and study on hepatocyte-targeting efficiency in vitro and in vivo.

Authors:  Yan Xiao; Huafang Zhang; Zhaoguo Zhang; Mina Yan; Ming Lei; Ke Zeng; Chunshun Zhao
Journal:  Int J Nanomedicine       Date:  2013-08-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.